Researchers develop vaccine to fight opioid misuse, addiction

Immunizations for the flu, smallpox and polio are essential in protecting against dangerous diseases. Now, widespread opioid addiction has pushed researchers to develop a vaccine against the effects of overdose and misuse.

According to results presented at the National Meeting & Exposition of the American Chemical Society (ACS), researchers are developing a vaccine against the growing threat of opioid addiction. The vaccine was developed to prevent opioid receptors in the body from attaching to antibodies, a method that involved the linking together of the opioid molecules which are normally too small to block.

"There is an urgent need to discover effective medications to treat substance use disorders. Increasingly, drug users are turning to opioids and powerful synthetic versions of these drugs that can sometimes be as much as 100 times more potent than heroin," said Kim D. Janda, PhD, head of the vaccine research team.

Read the full story below:

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.